IONS
Ionis Pharmaceuticals Inc.
$76.38
+$0.82(+1.09%)
49
Overall
40
Value
54
Tech
55
Quality
Market Cap
$10.76B
Volume
321.32K
52W Range
$32.00 - $86.74
Target Price
$103.55
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $346.6M | $514.2M | $599.7M | $1.1B | $729.3M | $810.5M | $587.4M | $787.6M | $705.1M | $943.7M | ||
| Total Revenue | $346.6M | $514.2M | $599.7M | $1.1B | $729.3M | $810.5M | $587.4M | $787.6M | $705.1M | $943.7M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $416.4M | $4.4M | $11.9M | $10.8M | $14.1M | $9.1M | $11.2M | $15.9M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $346.6M | $514.2M | $183.3M | $1.1B | $717.3M | $799.6M | $573.3M | $778.5M | $693.9M | $927.8M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $392.9M | $483.1M | $244.6M | $286.6M | $354.3M | $186.3M | $983.4M | $232.6M | $1.2B | $1.3B | ||
| Research & Development | $-340.4M | $-372.5M | $-411.9M | $461.5M | $531.0M | $638.2M | -- | -- | $901.5M | $915.6M | ||
| Research Expense | $-340.4M | $-372.5M | $-411.9M | $461.5M | $531.0M | $638.2M | -- | -- | $901.5M | $915.6M | ||
| Selling, General & Administrative | $48.6M | $108.5M | $244.6M | $286.6M | $354.3M | $186.3M | $150.3M | $232.6M | $267.5M | $393.9M | ||
| General & Administrative Expenses | $48.6M | $108.5M | $244.6M | $286.6M | $354.3M | $186.3M | $150.3M | $232.6M | $267.5M | $393.9M | ||
| Amortization | $-25.1M | $-32.5M | $-35.2M | $39.3M | $3.2M | $5.0M | $5.4M | $6.3M | $6.7M | -- | ||
| Other Operating Expenses | $344.3M | $374.6M | $-3.1M | $-1.6M | $-1.5M | $-1.4M | $997.6M | $1.1B | $1.2B | $1.3B | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-46.3M | $31.0M | $-61.4M | $365.9M | $-172.1M | $-30.2M | $-410.2M | $-353.7M | $-475.1M | $-381.7M | ||
| EBITDA | $2.8M | $79.3M | $15.3M | $443.3M | $-111.2M | $-5.2M | $-227.7M | $-292.5M | $-414.4M | $-332.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $38.8M | $44.8M | $44.8M | $48.8M | $6.2M | $4.4M | $2.8M | $12.7M | $17.0M | $17.3M | ||
| Net Non-Operating Interest Income/Expense | $-33.3M | $-36.6M | $-14.6M | $-48.8M | $-9.5M | $-9.3M | $8.1M | $-12.7M | $-17.0M | $-17.3M | ||
| Gain on Sale of Securities | -- | -- | -- | $52.2M | $47.1M | $20.1M | $18.0M | $87.1M | $104.1M | $108.0M | ||
| Other Income/Expense | $4.0M | $11.2M | $182.0K | $-29.7M | $-47.0M | $-10.4M | $160.3M | $-101.2M | $-105.5M | $-92.6M | ||
| Other Special Charges | $-4.0M | $-3.5M | $-182.0K | $-22.6M | $-62.0K | $-9.8M | $-7.3M | $14.3M | $1.3M | $-15.4M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | $2.3M | $800.0K | $800.0K | $-2.2M | $-1.9M | $-2.7M | -- | -- | -- | -- | ||
| Impairment of Capital Assets | $-2.3M | $-800.0K | $-800.0K | $2.2M | $1.9M | $2.7M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-44.8M | $28.0M | $-31.4M | $395.5M | $-128.4M | $-24.7M | $-255.2M | $-321.3M | $-443.1M | $-362.3M | ||
| Pre-Tax Income | $-83.6M | $-16.8M | $-76.2M | $346.8M | $-134.6M | $-29.1M | $-258.0M | $-334.0M | $-460.1M | $-379.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $2.9M | $-6.0M | $-291.1M | $43.5M | $345.2M | $-551.0K | $11.7M | $32.3M | $-6.2M | $1.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $-86.6M | $346.0K | $273.7M | $294.1M | $-444.3M | $-28.6M | $-269.7M | $-366.3M | $-453.9M | $-381.4M | ||
| Net Income (Continuing Operations) | $-86.6M | $346.0K | $273.7M | $294.1M | $-444.3M | $-28.6M | $-269.7M | $-366.3M | $-453.9M | $-381.4M | ||
| Net Income (Discontinued Operations) | $-86.6M | $346.0K | $273.7M | $294.1M | $-444.3M | $-28.6M | $-269.7M | $-366.3M | $-453.9M | $-381.4M | ||
| Net Income (Common Stockholders) | $-86.6M | $346.0K | $273.7M | $1.2B | $-444.3M | $-28.6M | $-269.7M | $-366.3M | $-453.9M | $-381.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-29.7M | -- | -- | -- | $-375.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $392.9M | $483.1M | $661.0M | $291.0M | $366.3M | $197.2M | $997.6M | $241.8M | $1.2B | $1.3B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $120.9M | $124.0M | $132.3M | $140.0M | $139.6M | $141.0M | $141.8M | $143.2M | $149.5M | $160.0M | ||
| Average Shares Outstanding (Diluted) | $124.0M | $126.1M | $134.1M | $142.9M | $139.6M | $141.0M | $141.8M | $143.2M | $149.5M | $160.0M | ||
| Shares Outstanding | $123.7M | $125.4M | $138.4M | $139.2M | $140.9M | $141.7M | $143.0M | $145.8M | $159.0M | $165.3M | ||
| Basic EPS | $-0.72 | $0.08 | $2.09 | $2.12 | $-3.23 | $-0.20 | $-1.9 | $-2.56 | $-3.04 | $-2.38 | ||
| Basic EPS (Continuing Operations) | $-0.72 | $0.08 | $2.09 | $2.12 | $-3.23 | $-0.20 | $-1.9 | $-2.56 | $-3.04 | $-2.38 | ||
| Diluted EPS | $0.21 | $0.08 | $2.07 | $2.08 | $-3.23 | $-0.20 | $-1.9 | $-2.56 | $-3.04 | $-2.38 | ||
| Diluted EPS (Continuing Operations) | $0.21 | $0.08 | $2.07 | $2.08 | $-3.23 | $-0.20 | $-1.9 | $-2.56 | $-3.04 | $-2.38 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D Income | $56.0K | $-7.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | $-7.7M | -- | -- | -- | -- | $149.6M | $-161.0K | $-12.0K | -- | ||
| Minority Interests | -- | $11.1M | $58.8M | $-9.1M | $35.5M | -- | -- | -- | -- | -- | ||
| Other Gand A | $48.6M | $108.5M | $244.6M | $286.6M | $354.3M | $186.3M | $150.3M | $232.6M | $267.5M | $393.9M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IONS | $76.38 | +1.1% | 321.32K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ionis Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW